Myasthenia Gravis Clinical Trial
Official title:
The FBIndex to Determine the Risk of Falls and Its Translation to Assistive Gait Device Care for Patients With Neuromuscular Disorders
The combination of short quantitatively assessing muscular function and balance in combination with short clinical scores, can be a new valid approach to evaluate the patient risk of fall and help to create a quick checkup test to prescribe an appropriate assistive device. The primary goal of this project is to provide a short battery of clinical assessments used to determine risk of falling for patients with neuromuscular diseases (NMD) based on correlation between clinical assessments between two groups of NMD patients and scales used to assess risk of falling for patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05039190 -
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
|
Phase 3 | |
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT01727193 -
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
|
Phase 3 | |
| Completed |
NCT00285350 -
Mycophenolate Mofetil in Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT05694234 -
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
|
||
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Not yet recruiting |
NCT05095103 -
Immune Profiles in Myasthenia Gravis
|
||
| Not yet recruiting |
NCT04965987 -
Oxaloacetate in Myasthenia Gravis
|
Phase 1 | |
| Completed |
NCT02066519 -
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
|
N/A | |
| Terminated |
NCT02102594 -
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
|
Phase 2 | |
| Completed |
NCT02774239 -
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
|
Phase 3 | |
| Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
| Terminated |
NCT01828294 -
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
|
Phase 1 | |
| Terminated |
NCT00727194 -
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT04590716 -
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
|
||
| Recruiting |
NCT04837625 -
Study of Myasthenic Crisis in China
|
||
| Not yet recruiting |
NCT01469858 -
Perception and Multisensory Integration in Neurological Patients Using fMRI
|
N/A | |
| Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
| Completed |
NCT03205306 -
Myasthenia Gravis and Psyche
|
||
| Recruiting |
NCT06106672 -
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
|
Phase 1/Phase 2 |